Last reviewed · How we verify

Civi Biopharma, Inc. — Portfolio Competitive Intelligence Brief

Civi Biopharma, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Iloprost Injection, for intravenous use Iloprost Injection, for intravenous use phase 3 Prostacyclin analog Prostacyclin receptor (IP receptor) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AOP Orphan Pharmaceuticals AG · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Liquidia Technologies, Inc. · 1 shared drug class
  4. Ludwig-Maximilians - University of Munich · 1 shared drug class
  5. Lung Biotechnology PBC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Civi Biopharma, Inc.:

Cite this brief

Drug Landscape (2026). Civi Biopharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/civi-biopharma-inc. Accessed 2026-05-16.

Related